Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02693171 · ClinicalTrials.gov registry record
Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients
A clinical trial, sponsored by United Therapeutics.
- Terminated
- Registry status
- 13
- Enrollment target
NCT02693171 is a clinical trial that was terminated before completion, run by United Therapeutics. The registered enrollment target is 13 participants.
The verdict
NCT02693171 was terminated before completion, sponsored by United Therapeutics.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the incidence of human anti-chimeric antibody (HACA) in high-risk neuroblastoma patients treated with Unituxin combination therapy.
Interventions
- DRUG Dinutuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-03-15 |
| Est. Completion | 2016-12-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02693171
The ClinicalTrials.gov registry entry for NCT02693171 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dinutuximab is the first listed.
NCT02693171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02693171 about?
NCT02693171 is a clinical study titled "Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients". The purpose of this study was to assess the incidence of human anti-chimeric antibody (HACA) in high-risk neuroblastoma patients treated with Unituxin combination therapy.
What is the current status of trial NCT02693171?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2016-03-15. Estimated completion is 2016-12-19.
What interventions are being tested in trial NCT02693171?
The interventions under investigation include: Dinutuximab (DRUG).
Who is sponsoring clinical trial NCT02693171?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.